Oncoparse develops a non-invasive diagnostic tool for pancreatic cancer utilizing circulating tumor DNA (ctDNA) and advanced sequencing. The platform employs proprietary algorithms to deliver comprehensive genetic and epigenetic insights for clinicians. This technology aims to enable earlier detection and support personalized treatment decisions to improve patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Pancreatic cancer is often diagnosed late due to non-specific symptoms and the limitations of current diagnostic methods. Late diagnosis contributes to low survival rates and limited treatment options for patients.
Solution
Oncoparse is developing a non-invasive diagnostic tool that uses circulating tumor DNA (ctDNA) from liquid biopsies to improve the early detection and monitoring of pancreatic cancer. The technology employs advanced sequencing technologies and proprietary bioinformatics algorithms to enhance variant calling and deliver comprehensive genetic and epigenetic insights. This enables clinicians to make more informed, personalized treatment decisions, with the goal of improving patient outcomes and survival rates. The diagnostic solution aims to provide reliable, rapid, and actionable insights for better patient care.
Target Audience
The primary audience includes clinicians, researchers, and patients involved in pancreatic cancer diagnosis, treatment, and research.
Features
- Non-invasive diagnostic tool using liquid biopsies
- Analysis of circulating tumor DNA (ctDNA)
- Advanced sequencing technologies for comprehensive genetic insights
- Proprietary bioinformatics algorithms to enhance variant calling
- Delivers genetic and epigenetic insights